Sequenom Is Recovering on Some Good News

Before you go, we thought you'd like these...
Before you go close icon

The last couple of weeks have been quite encouraging for Sequenom . The company's stock rallied almost 35% since Nov. 7 following the third-quarter earnings report after market close. The company beat analyst estimates for both revenue and EPS by $3.4 million and $0.03, respectively. The news came as sweet relief after the company lost a patent ruling last month and its stock price sunk as much as 23%, garnering negative sentiment.

Sequenom has managed to increase the number of covered lives for its MaterniT21 PLUS non-invasive prenatal test to approximately 90 million in the U.S., and it expects to reach its goal of 120 million lives by the end of 2013. The company is receiving payments from all major national players, which is a healthy sign since the reimbursement environment has been challenging. Furthermore, the company reported an increased focus on the tests with acceptable reimbursements, with total of 48,300 tests accessioned. A total of 38,600 MaterniT21 PLUS tests were run in the third quarter, a 2% increase from the previous quarter.

Financial results
Sequenom's reported revenue for the third quarter of 2013 was $44 million, a 92% increase from the comparable period of 2012 and a 26% increase from the previous quarter of 2013. The increase was due to an increase in the company's revenue, recognized on cash from the Diagnostic Services of the company; a 166% increase was reported compared to the third quarter of 2012 and 36% to the previous quarter of 2013.


Sequenom reported net loss of $28.1 million for third quarter; as compared to $31 million for the previous quarter, this represents an almost 9.4% decrease. The R&D and SG&A expenses were down from the previous quarter. The company incurred restructuring charges of approximately $6 million associated with elimination of about 75 positions, however, as well as the decision to not occupy additional office space that had been leased. The restructuring is expected to decrease $13 million of personnel and facilities costs in 2014.

The cash and equivalents of the company as of Sept. 30 were $84.7 million, with a cash burn of $22.2 million. The cash burn came down almost 50% from the previous quarter's $44.2 million. The company has improved its cash collection methods and currently has $46 million-$51 million in uncollected amounts, made up of revenue not recognized on tests delivery.

The company is implementing programs to increase the reimbursement payments and to reduce the uncompensated Medicaid tests. This will result in increased revenue when the payments are recognized.

Bottom line
Sequenom is the pioneer in the NIPT industry and further strengthened its position with additional content for MaterniT21 PLUS test. The test has now started to report subchromosomal micro-deletions and autosomal trisomies presence for chromosomes 16 and 22, which should provide further value to health care professionals and patients.

The company reported results that were significantly higher than analyst estimates, which resulted in a surge in the company's stock price and positive investor sentiment. Sequenom was recently reiterated as a "buy" by the Maxim Group following its strong third-quarter results. The investor faith in the company has been slightly restored following the earnings release.

The company has promising products, and the commercialization of its MassArray System has the potential to bring increased value and profit to the company. All investments in development-stage biotechnology companies carry an inherent risk, however, so investors are encouraged to do their own due diligence before making any investment in Sequenom.

Another growth stock with room to run
This incredible tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!

The article Sequenom Is Recovering on Some Good News originally appeared on Fool.com.

Mohsin Saeed has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners

Man's Wife Leaves Him And Their Kids After A Fight - Two Days Later He Posts This Man's Wife Leaves Him And Their Kids After A Fight - Two Days Later He Posts This
15 Recall the Kindest Thing a Stranger Ever Did for Them 15 Recall the Kindest Thing a Stranger Ever Did for Them
Man Finds 5 Abandoned 'Puppies' In His Garden - Then Quickly Realizes He Made A Big Man Finds 5 Abandoned 'Puppies' In His Garden - Then Quickly Realizes He Made A Big